Studying drug effects on the Proteome

Over the past decade, our ability to identify molecular mechanisms underlying disease and study drug action by mass spectrometry-based proteomics has progressed remarkably. Improved instrumentation and new experimental approaches allow studying cellular and tissue phenotypes in a disease context, as well as upon modulation by bioactive molecules, with unprecedented resolution and dimensionality. Furthermore, the diversification of direct and indirect target identification methodologies allows for comprehensive analysis of cellular targets of bioactive compounds in live cells and the correlation between target engagement and proteotype effects. This talk focusses on the emerging role of mass spectrometry based proteomics in drug discovery and highlights experimental approaches and applications with impact for understanding efficacy and safety of drug candidates.

Short Bio:
Marcus Bantscheff graduated in Chemistry at the University of Konstanz and obtained his PhD degree from the University of Rostock working with Prof. Glocker on structure-function correlation of bacterial response regulator proteins utilizing mass spectrometric and protein chemistry methods. As a postdoctoral fellow at the Proteome Center in Rostock, Marcus was involved in setting up a proteomics unit and focused on the analysis of synovial fluids and tissue samples derived from rheumathoid arthritis patients and CIA mice. At Cellzome since 2002, he focuses on the development and application of proteomics and chemical biology approaches to characterize targets and mechanism-of-action of bioactive molecules. Marcus is an inventor on several patents including Cellzome’s Kinobeads™ technology, has co-authored more than 70 publications (h-index 38), and serves as a reviewer for reputed journals and funding bodies. He is a member of the scientific advisory board of Denator AB, the industry advisory board of Hochschule Mannheim and editorial board of Molecular and Cellular Proteomics. In 2016 his research was awarded with the Life Science price of the German Society for Mass Spectrometry. Marcus is a Senior Scientific Director at GSK and a Senior Fellow and in his current position, he leads the proteomics platform at Cellzome, A GSK company.